University of Southern California
USC Norris Comprehensive Cancer Center

Amir Goldkorn, M.D.

Photograph of Amir Goldkorn

Amir Goldkorn, M.D., is Co-Leader of the Translational and Clinical Science Program (TACS) at the USC Norris Comprehensive Cancer Center. He is an Associate Professor of Medicine with Tenure at the Keck School of Medicine of the University of Southern California.

Dr. Goldkorn is a board certified medical oncologist who is clinically subspecialized in genitourinary malignancies. His laboratory's research focuses on developing the therapeutic and prognostic potential of circulating tumor cells (CTCs), cancer stem cells, and telomerase. Dr. Goldkorn's team is leading CTC studies in phase III multi-center prostate and bladder cancer trials and also conducting mechanistic studies in mouse models of cancer dissemination. Dr. Goldkorn also founded and directs a CTC Research Core at USC Norris. In the area of cancer stem cells, Dr. Goldkorn's group discovered that cancer cells can cyclically lose and regain cancer stem-like properties, and their current work is focused on elucidating the mechanisms that mediate this plasticity. Dr. Goldkorn's team also is currently working to develop a novel cancer therapeutic strategy that interferes with the enzyme telomerase to kill cancer cells. Collectively, these research efforts are aimed at surmounting cancer heterogeneity and providing powerful new tools for precision cancer care.

Dr. Goldkorn obtained his Bachelor's Degree from Harvard University (magna cum laude) and his Medical Degree at the University of California, Los Angeles (UCLA), where he also completed his Internal Medicine residency. Subsequently, he trained in Hematology/Oncology at the University of California, San Francisco (UCSF), where he then remained for 3 additional years of postdoctoral research in the laboratory of Elizabeth Blackburn, a Nobel Laureate and discoverer of telomerase, the enzyme that lengthens and protects chromosome ends (telomeres).

Since joining the USC faculty in 2007, Dr. Goldkorn has served as principal investigator of several NIH and foundation grants, and his research has been published in Lancet Oncology, Cancer Research, Journal of Clinical Oncology, and Journal of the National Cancer Institute, among others. He serves as a reviewer and editorial board member for several scientific journals as well as national and international grant review panels. Dr. Goldkorn was the recipient of the American Society of Clinical Oncology Young Investigator Award and the Western American Federation of Medical Research (WAFMR) Outstanding Investigator Award. He has been elected to the Western Society of Clinical Investigation and is currently Chair-elect of WAFMR.